Evidence review · Drug selection
Zepbound for sleep apnea: what SURMOUNT-OSA actually showed
The honest verdict
For obstructive sleep apnea with obesity, tirzepatide (Zepbound) is the clear evidence-based choice — SURMOUNT-OSA led the FDA to approve it as the first drug for this indication, with apnea events falling roughly 25-30 per hour. Coverage is often easier under the OSA indication than for weight loss alone.
The options, side-by-side
| Drug | Trial evidence | Fit note |
|---|---|---|
| Tirzepatide (Zepbound) | SURMOUNT-OSA: AHI −25 to −30 events/hr | FDA-approved for OSA with obesity — the evidence-based choice |
| Semaglutide (Wegovy) | No OSA indication; weight loss improves OSA indirectly | Reasonable if Zepbound is unavailable, but no OSA label |
| CPAP (comparison, not a drug) | Long-standing first-line OSA therapy | Often continued alongside; not replaced without a repeat sleep study |
| Tirzepatide (Mounjaro) | Same molecule, diabetes label | Used when the diabetes indication is the covered route |
Drug selection is a prescriber decision. This table summarizes the trial evidence — it is not a prescription or a substitute for clinical judgment.
What SURMOUNT-OSA actually measured
SURMOUNT-OSA (Malhotra et al., NEJM 2024) enrolled adults with obesity and moderate-to-severe obstructive sleep apnea, across two arms — patients using CPAP and patients not using it. The primary endpoint was change in the apnea-hypopnea index (AHI), the number of breathing interruptions per hour of sleep.
Tirzepatide reduced AHI by roughly 25-30 events per hour more than placebo, a large effect in a condition where a drop of 15 events per hour is clinically meaningful. Benefits held in both the CPAP-using and CPAP-free arms. On the strength of this, the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity — the first drug ever approved for this indication.
- Malhotra A et al. — Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA) — New England Journal of Medicine, 391:1193-1205, 2024
Why weight loss improves sleep apnea
Obstructive sleep apnea in obesity is driven substantially by fat deposition around the upper airway and in the neck, plus reduced lung volume from abdominal fat, which makes the airway more collapsible during sleep. Losing that fat mechanically widens and stabilizes the airway.
This is why the effect tracks weight loss magnitude — and why tirzepatide, the most potent weight-loss agent, produced the largest AHI improvement. It also means the benefit is not instantaneous: expect AHI improvement to follow the weight-loss curve over months, not weeks.
Can you stop CPAP? Not on your own
Some SURMOUNT-OSA patients improved enough to reach AHI levels that would no longer meet the diagnostic threshold for moderate-to-severe OSA. That is a real and meaningful outcome. But it does not mean you should stop CPAP based on weight loss alone.
The correct process is a repeat sleep study after substantial weight loss, interpreted by your sleep physician, who decides whether therapy can be reduced or stopped. Untreated OSA carries cardiovascular and daytime-safety risks (including driving), so this is a decision to make with data, not by feel. Many patients continue CPAP at lower pressure rather than stopping outright.
The coverage advantage of an OSA diagnosis
A documented moderate-to-severe OSA diagnosis is one of the most useful things a patient can bring to a GLP-1 coverage conversation. Because Zepbound now carries an FDA-approved OSA indication, plans that exclude weight-loss drugs may still cover it for OSA — and this includes some Medicare plans, where the obesity carve-out otherwise blocks coverage.
Practically: get the sleep-study report and AHI number into your prior-authorization documentation. If you suspect undiagnosed OSA (loud snoring, witnessed pauses, morning headaches, daytime sleepiness), a sleep study can both improve your health and open a coverage path. See our cost-lowering menu for the full appeal playbook.
How to talk to your prescriber
Bring your sleep-study report with the AHI number, your CPAP adherence data if you use one (most machines report it), and your BMI. The AHI and the obesity diagnosis together are what establish the FDA-approved indication.
Useful questions: "Does my AHI qualify me for the Zepbound OSA indication?" "Will my plan cover it under OSA even though it excludes weight-loss drugs?" "When should I repeat the sleep study to reassess CPAP?" Loop in your sleep physician alongside the prescriber — the two decisions are linked.
Frequently asked
Is Zepbound really FDA-approved for sleep apnea?
Yes. Following the SURMOUNT-OSA trial, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug approved for this indication. Semaglutide does not currently carry an OSA indication.
How much does a GLP-1 improve sleep apnea?
In SURMOUNT-OSA, tirzepatide reduced the apnea-hypopnea index by roughly 25-30 more events per hour than placebo — a large effect where a 15-event reduction is already clinically meaningful. Benefits appeared in patients both using and not using CPAP.
Can I stop using CPAP if I lose weight on a GLP-1?
Only after a repeat sleep study interpreted by your sleep physician. Some patients improve enough to fall below the moderate-to-severe threshold, but untreated OSA carries real cardiovascular and driving-safety risks. Many patients continue CPAP at a lower pressure rather than stopping.
Will insurance cover Zepbound for sleep apnea if it excludes weight-loss drugs?
Often, yes — that is the practical value of the OSA indication. Because it is an FDA-approved medical indication rather than weight loss, plans that carve out obesity drugs may still cover it, including some Medicare plans. Get your sleep-study AHI into the prior-authorization documentation.
Next steps
Other situations
Your situation may span more than one of these. Each guide reads the trial evidence for a different starting point.
For women
The best GLP-1 for women: what the trial evidence actually supports
For men
The best GLP-1 for men: what the trial evidence actually supports
For adults over 50
The best GLP-1 for adults over 50: what the evidence supports
For women with PCOS
Ozempic for PCOS: what the evidence actually supports
For people with insulin resistance or prediabetes
The best GLP-1 for insulin resistance and prediabetes
For people with type 2 diabetes
Ozempic vs Mounjaro for type 2 diabetes: which controls blood sugar better?
For people who have had bariatric surgery
The best GLP-1 after bariatric surgery: managing weight regain
For people with a BMI of 40 or higher
The best GLP-1 for BMI 40+: severe obesity and the surgery question
Sources
- Malhotra A et al. — SURMOUNT-OSA — New England Journal of Medicine, 391:1193-1205, 2024
- Zepbound (tirzepatide) FDA prescribing information — US FDA
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 387:205-216, 2022
This page describes published evidence and is not medical advice. GLP-1 drug selection is a decision for a licensed prescriber who has assessed you individually.